Literature DB >> 22872232

Ranolazine-induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits.

Isaac Aidonidis1, Konstantinos Doulas, Apostolia Hatziefthimiou, Georgios Tagarakis, Vassilios Simopoulos, Ioannis Rizos, Nikolaos Tsilimingas, Paschalis-Adam Molyvdas.   

Abstract

Ranolazine (Ran) is a novel anti-ischemic agent with electrophysiologic properties mainly attributed to the inhibition of late Na(+) current and atrial-selective early Na(+) current. However, there are only limited data regarding its efficacy and mechanism of action against atrial flutter (Afl) and atrial fibrillation (AF) in intact animals. Therefore, we aimed to investigate the electrophysiologic mechanism of Ran in a rabbit model of inducible atrial tachyarrhythmias elicited by acetylcholine (ACh). Arrhythmias were produced in 19 rabbits by rapid atrial burst pacing during control, after intravenous ACh and after Ran + ACh administration. Recording of right atrial monophasic action potentials (MAPs) and programmed stimulation were utilized to determine the duration of atrial repolarization at various cycle lengths and voltage levels of action potential, including 75% of total MAP duration (MAPD75), effective refractory period (ERP), and postrepolarization refractoriness (PRR = ERP - MAPD75) prior to and after Ran. Control stimulation yielded no arrhythmias or maximal nonsustained runs of Afl/AF. Upon ACh, 17 of 19 rabbits exhibited sustained Afl and AF as well as mixed forms of Afl/AF, while 2 animals revealed none or short runs of nonsustained arrhythmias and were excluded from the study. High-frequency burst pacing during the first 30 minutes after Ran + ACh failed to induce any arrhythmia in 13 of 17 rabbits (76%), while 2 animals displayed sustained Afl/AF and 2 other animals nonsustained Afl/AF. At basic stimulation cycle length of 250 milliseconds, Ran prolonged baseline atrial ERP (80 ± 8 vs 120 ± 9 milliseconds, P < .001) much more than MAPD75 (65 ± 7 vs 85 ± 7 milliseconds, P < .001), leading to atrial PRR which was more pronounced after Ran compared with control measurements (35 ± 11 vs 15 ± 10 milliseconds, P < .001). This in vivo study demonstrates that Ran exerts antiarrhythmic activity by suppressing inducibility of ACh-mediated Afl/AF in intact rabbits. Its action may predominantly be related to a significant increase in atrial PRR, resulting in depressed electrical excitability and impediment of arrhythmia initiation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22872232     DOI: 10.1177/1074248412453874

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  7 in total

1.  Effect of berberine on acetylcholine-induced atrial fibrillation in rabbit.

Authors:  Zhi-Wen Zhou; Hong-Chao Zheng; Li-Fang Zhao; Wei Li; Jian-Wen Hou; Yi Yu; Pi-Zhi Miao; Jian-Ming Zhu
Journal:  Am J Transl Res       Date:  2015-08-15       Impact factor: 4.060

2.  Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study.

Authors:  V Simopoulos; G Tagarakis; A Hatziefthimiou; I Skoularigis; F Triposkiadis; V Trantou; N Tsilimingas; I Aidonidis
Journal:  Clin Res Cardiol       Date:  2014-08-19       Impact factor: 5.460

3.  A peptidomimetic inhibitor suppresses the inducibility of β1-adrenergic autoantibody-mediated cardiac arrhythmias in the rabbit.

Authors:  Hongliang Li; Ling Zhang; Bing Huang; Vineet Veitla; Benjamin J Scherlag; Madeleine W Cunningham; Christopher E Aston; David C Kem; Xichun Yu
Journal:  J Interv Card Electrophysiol       Date:  2015-10-07       Impact factor: 1.900

4.  The Effects of Ranolazine on Paroxysmal Atrial Fibrillation in Patients with Coronary Artery Disease: A Preliminary Observational Study.

Authors:  Dionyssios Leftheriotis; Panayota Flevari; George Theodorakis; Angelos Rigopoulos; Ignatios Ikonomidis; Fotis Panou; Vassilios Sourides; Panagiotis Simitsis; Georgios Giannakakis; Isaac Aidonidis; Ioannis Rizos; Maria Anastasiou-Nana
Journal:  J Atr Fibrillation       Date:  2014-02-28

5.  Phospho-ablation of cardiac sodium channel Nav1.5 mitigates susceptibility to atrial fibrillation and improves glucose homeostasis under conditions of diet-induced obesity.

Authors:  Revati S Dewal; Amara Greer-Short; Cemantha Lane; Shinsuke Nirengi; Pedro Acosta Manzano; Diego Hernández-Saavedra; Katherine R Wright; Drew Nassal; Lisa A Baer; Peter J Mohler; Thomas J Hund; Kristin I Stanford
Journal:  Int J Obes (Lond)       Date:  2021-01-26       Impact factor: 5.095

6.  Ranolazine for atrial fibrillation: buy one get three beneficial mechanisms!

Authors:  Lars S Maier
Journal:  Eur J Heart Fail       Date:  2012-10-30       Impact factor: 15.534

Review 7.  Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning.

Authors:  Sarah Rouhana; Anne Virsolvy; Nassim Fares; Sylvain Richard; Jérôme Thireau
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.